- Home
- Publications
- Publication Search
- Publication Details
Title
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 110, Issue 48, Pages 19519-19524
Publisher
Proceedings of the National Academy of Sciences
Online
2013-11-12
DOI
10.1073/pnas.1319583110
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Identification ofROS1rearrangement in gastric adenocarcinoma
- (2013) Jeeyun Lee et al. CANCER
- Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1
- (2013) Mark M. Awad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target
- (2013) A. Saborowski et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer
- (2012) K. D. Davies et al. CLINICAL CANCER RESEARCH
- Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non-Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion
- (2012) V. M. Rimkunas et al. CLINICAL CANCER RESEARCH
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- ROS1 as a ‘druggable’ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway
- (2012) Sai-Hong Ignatius Ou et al. Expert Review of Anticancer Therapy
- A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors
- (2012) Geoffrey I. Shapiro et al. INVESTIGATIONAL NEW DRUGS
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- RET, ROS1 and ALK fusions in lung cancer
- (2012) Kengo Takeuchi et al. NATURE MEDICINE
- Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
- (2012) Levi A. Garraway et al. Cancer Discovery
- Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen
- (2011) Sen Zhang et al. Chemical Biology & Drug Design
- Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma
- (2011) Ting-Lei Gu et al. PLoS One
- Chromosome 3 Anomalies Investigated by Genome Wide SNP Analysis of Benign, Low Malignant Potential and Low Grade Ovarian Serous Tumours
- (2011) Ashley H. Birch et al. PLoS One
- A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
- (2010) J. P. Eder et al. CLINICAL CANCER RESEARCH
- Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia
- (2010) T. O'Hare et al. CLINICAL CANCER RESEARCH
- Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
- (2010) Geoffrey R. Oxnard et al. CLINICAL CANCER RESEARCH
- A Comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors
- (2010) Aung Naing et al. INVESTIGATIONAL NEW DRUGS
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases
- (2009) F. Qian et al. CANCER RESEARCH
- GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers
- (2009) P. Sabbatini et al. MOLECULAR CANCER THERAPEUTICS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now